Not a member? Register Now
By linking my Doximity account with UPMC Physician Resources, I acknowledge that:
By linking my Doximity account with UPMC Physician Resources, I acknowledge that:
Forgot your password? Enter the email address you used to create your account to initiate a password reset.
UPMC has been selected as a center for the GALACTIC Study, a double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of omecamtiv mecarbil on mortality and morbidity in subjects with chronic heart failure with reduced ejection fraction
We are currently enrolling men and women who have been diagnosed with heart failure with a reduced ejection fraction. The primary purpose of this study is to evaluate the effectiveness of the study drug, omecamtiv mecarbil, compared to placebo plus background standard-of-care therapy, to time of cardiovascular death or first heart failure exacerbation.
Omecamtiv mecarbil acts as a cardiac myosin activator, targeting the myocardial contractility. It is shown to reduce LV filling pressures and total peripheral vascular resistance.
Potential candidates for GALACTIC must meet the following primary inclusion criteria:
For a full list of inclusion/exclusion criteria or to refer a patient:
Marc Simon, MD, is the principal investigator at UPMC. If you know a patient you believe may qualify, please call Mary Kunkel, RN, BSN, research nurse coordinator at 412-647-4463 or email HeartFailureClinicalTrials@upmc.edu.
